Economic Advantages of Original Container Closure Systems in Combination Product Development: Scenarios with Expert Validation and Industry-Quantified Cost-Time Savings.

Q3 Medicine
Mehul Desai, Daniel Waites, William Rich, Lawton Laurence, Shirish Ingawale, Fran DeGrazio
{"title":"Economic Advantages of Original Container Closure Systems in Combination Product Development: Scenarios with Expert Validation and Industry-Quantified Cost-Time Savings.","authors":"Mehul Desai, Daniel Waites, William Rich, Lawton Laurence, Shirish Ingawale, Fran DeGrazio","doi":"10.5731/pdajpst.2025-000002.1","DOIUrl":null,"url":null,"abstract":"<p><p>Many on-body delivery systems (OBDSs) for subcutaneous (SC) delivery require a change in primary container closure system (CCS). This necessitates compatibility and stability testing with original packaging materials and distribution and assembly, which are often laborious and time-consuming. Exploring new primary CCSs rather than using an original CCS can introduce risks, prolong timelines, and increase costs. In this study, 21 US-based combination product experts completed a double-blinded online survey between 6 October and 20 November 2023. The survey included 15 screening questions and 23 survey questions, including questions about compatibility issues between new CCSs and drugs and stability testing for new CCSs. The largest proportion of participants (28.6%) reported that 5-10% of products they had worked directly on had experienced compatibility issues between a new CCS and a drug, with a weighted average of 11.9%. The most common compatibility issues were particulate challenges in 55.6%, sterility in 27.8%, and leachables in 16.7%. Most respondents (76.2%) rated the timeline showing that using an OCC can save 12-24 months as somewhat (38.1%) or very (38.1%) representative. Most participants (57.1%) estimated that the range of direct costs, including development costs, drug product, engineering runs, line changes, and other costs, when using an OBDS with a new CCS is $1015 million, 38.1% estimated <$10 million, and 4.8% estimated $2125 million. Most participants (80.9%) reported that challenges in the primary CCS qualification/validation process delay entry of combination products into clinical trials or delay their commercial launch. The weighted average of the delay was 9.7 months. Using an original CCS during combination product development would therefore be of significant economic benefit to the development of combination products in terms of time, cost, and risk.</p>","PeriodicalId":19986,"journal":{"name":"PDA Journal of Pharmaceutical Science and Technology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PDA Journal of Pharmaceutical Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5731/pdajpst.2025-000002.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Many on-body delivery systems (OBDSs) for subcutaneous (SC) delivery require a change in primary container closure system (CCS). This necessitates compatibility and stability testing with original packaging materials and distribution and assembly, which are often laborious and time-consuming. Exploring new primary CCSs rather than using an original CCS can introduce risks, prolong timelines, and increase costs. In this study, 21 US-based combination product experts completed a double-blinded online survey between 6 October and 20 November 2023. The survey included 15 screening questions and 23 survey questions, including questions about compatibility issues between new CCSs and drugs and stability testing for new CCSs. The largest proportion of participants (28.6%) reported that 5-10% of products they had worked directly on had experienced compatibility issues between a new CCS and a drug, with a weighted average of 11.9%. The most common compatibility issues were particulate challenges in 55.6%, sterility in 27.8%, and leachables in 16.7%. Most respondents (76.2%) rated the timeline showing that using an OCC can save 12-24 months as somewhat (38.1%) or very (38.1%) representative. Most participants (57.1%) estimated that the range of direct costs, including development costs, drug product, engineering runs, line changes, and other costs, when using an OBDS with a new CCS is $1015 million, 38.1% estimated <$10 million, and 4.8% estimated $2125 million. Most participants (80.9%) reported that challenges in the primary CCS qualification/validation process delay entry of combination products into clinical trials or delay their commercial launch. The weighted average of the delay was 9.7 months. Using an original CCS during combination product development would therefore be of significant economic benefit to the development of combination products in terms of time, cost, and risk.

原始容器封闭系统在组合产品开发中的经济优势:专家验证和行业量化成本-时间节约方案。
许多用于皮下(SC)给药的体内给药系统(obds)需要改变主要的容器封闭系统(CCS)。这就需要对原始包装材料以及分销和组装进行兼容性和稳定性测试,这通常既费力又耗时。探索新的主要CCS而不是使用原始CCS可能会带来风险,延长时间表并增加成本。在这项研究中,21名美国联合产品专家在2023年10月6日至11月20日期间完成了一项双盲在线调查。调查包括15个筛选问题和23个调查问题,包括新CCSs与药物的相容性问题和新CCSs的稳定性测试问题。最大比例的参与者(28.6%)报告说,他们直接参与的产品中有5-10%遇到了新的CCS和药物之间的兼容性问题,加权平均值为11.9%。最常见的相容性问题是微粒挑战(55.6%),不育(27.8%)和可浸出性(16.7%)。大多数受访者(76.2%)认为使用OCC可以节省12-24个月的时间线有些(38.1%)或非常(38.1%)具有代表性。大多数参与者(57.1%)估计,当将OBDS与新的CCS结合使用时,直接成本范围(包括开发成本、药品成本、工程运行成本、生产线变更成本和其他成本)为10.15亿美元(38.1%)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
34
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信